Tumor-targeted interleukin-12 synergizes with entinostat to overcome PD-1/PD-L1 blockade-resistant tumors harboring MHC-I and APM deficiencies

• Jeffrey Schlom,
• Claudia Palena,
• Sofia R Gameiro,
• Lucas A Horn,
• Kristin C Hicks,
• Christine M Minnar,
• Paul L Chariou

Affiliations

Jeffrey Schlom

Laboratory of Tumor Immunology and Biology, National Cancer Institute, Bethesda, Maryland, USA

Claudia Palena

Laboratory of Tumor Immunology and Biology, National Cancer Institute, Bethesda, Maryland, USA

Sofia R Gameiro

Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA

Lucas A Horn

Laboratory of Tumor Immunology and Biology, National Cancer Institute, Bethesda, Maryland, USA

Kristin C Hicks

Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA

Christine M Minnar

Center for Immuno-Oncology, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA

Paul L Chariou

Center for Immuno-Oncology, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA